Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design

Bibliography

• Kumar V, Das S, Jameell S. The biology and pathogenesis of hepatitis viruses. Curr Sci 2010;98(3):312-25
   Google Scholar
• Thomas DL, Astemborski J, Rai RM, The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6
   PubMed Web of Science ®Google Scholar
• Tan S-L. Hepatitis C viruses: genomes and molecular biology. Horizon Biosci 2006
   Google Scholar
• Hepatitis C. World Health Organization. Fact sheet N 164 June 2011. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Last accessed in 22 July 2011]
   Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41
   PubMed Web of Science ®Google Scholar
• Feinstone SM, Kapikian AZ, Purcell RH, Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70
   PubMed Web of Science ®Google Scholar
• Alter MJ, Gerety RJ, Smallwood LA, Sporadic non-A non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93
   PubMed Web of Science ®Google Scholar
• Rauch A, Rickenbach M, Weber R, Un safe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• Chiron Corp. NANBV diagnostics and vaccines. EP0318216; 1989
   Google Scholar
• Simmonds P, Bukh J, Combet C, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962-73
   PubMed Web of Science ®Google Scholar
• US Health. Cloned genomes of infectious hepatitis C viruses and uses thereof. US7201911; 2007
   Google Scholar
• US Health. Cloned genome of infectious hepatitis C virus of genotype 2a and uses thereof. WO0075338; 2000
   Google Scholar
• US Health. Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines. US7070790; 2006
   Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6
   PubMed Web of Science ®Google Scholar
• Ploss A, Evans MJ, Gaysinskaya VA, Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457(7231):882-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Rothwangl K, Mesecar AD, Lamiridosins, hepatitis C virus entry inhibitors from lamium album. J Nat Prod 2009;72(12):2158-62
   PubMedGoogle Scholar
• NY Financial International Corp. Compositions and methods for treatment of liver disease. WO2008100547; 2008
   Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55(9):1350-9
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Jensen DM, Bernstein DE, Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004;99(8):1490-6
   PubMedGoogle Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against HCV virus. Nature 2005;436(7053):961-6
   PubMed Web of Science ®Google Scholar
• Stoll-Keller F, Barth H, Fafi-Kremer S, Development of Hepatitis C virus vaccines: Challenges and progress. Expert Rev Vaccines 2009;8(3):333-45
   PubMed Web of Science ®Google Scholar
• Tripep AB. Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics. US2008295185; 2008
   Google Scholar
• Mercer DF, Schiller DE, Elliott JF, Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-33
   PubMed Web of Science ®Google Scholar
• Tokyo Metropolitan Org Med Res and Toray Industries. Nucleic acid construct containing full-length genome of human Hepatitis C virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis C viral particles. WO2005080575; 2005
   Google Scholar
• Houghton M. Discovery of the hepatitis C virus. Liver Int 2009;29(s1):82-8
   PubMedGoogle Scholar
• Sen G. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81
   PubMed Web of Science ®Google Scholar
• Ishii S, Koziel JM. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128:133-47
   PubMed Web of Science ®Google Scholar
• Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009;29(6):843-66
   PubMedGoogle Scholar
• Hiroishi K, Eguchi J, Ishii S, Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. J Biomed Biotechnol 2010; Article ID 263810
   PubMedGoogle Scholar
• Holz HL, Warren A, Le Couteur DG, CD8+ T cell tolerance following antigen recognition on hepatocytes. J Autoimmun 2010;34:15-22
   PubMedGoogle Scholar
• Bertolino P, Bowen D, McCaughan G. Immunological parameters determining adaptive immune responses to hepatitis C virus infection. In: Jirillo E, editor. The use of IFNs in HCV disease: from biology to clinical application. Springer; NY: 2007. p. 339-70
   Google Scholar
• Univ Northeastern Ohio. Compositions and methods for modulating immunogenic responses by activating dendritic cells. WO2010120897; 2010
   Google Scholar
• US Gov Health & Human Serv. Inducing a T cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cellS. WO2004092386; 2004
   Google Scholar
• Charles JD, Elizabeth BL, Yuk FL. Immunotherapy of virus infection. US2010143405; 2010
   Google Scholar
• Chiron Corp. HCV immunoassays employing C domain antigens. US5350671; 1994
   Google Scholar
• Chiron Corp. Novel Hepatitis C E1 and E2 truncated polypeptides and methods of obtaining the same. WO9604301; 1996
   Google Scholar
• Chiron Corp. Hepatitis C virus asialoglycoproteins. WO9533053; 1995
   Google Scholar
• Biomerieux SA and Inst Nat Sante Rech Med. Composition comprising specific non-structural proteins of hepatitis C virus, useful as prophylactic or therapeutic vaccines, also related expression vectors, microorganisms and antibodies. FR2855758; 2004
   Google Scholar
• United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis. US5639594; 1997
   Google Scholar
• Akzo Nobel NV. Hepatitis C virus (HCV) non-structural-3 peptides, antibodies thereto and methods for the detection of HCV. WO9413699; 1994
   Google Scholar
• Peking University People S Hospital. Anti-HCV vaccine and preparation methods and uses thereof. US2010310605; 2010
   Google Scholar
• Transgene SA. Hepatitis C virus non structural fusion protein. MX2008011361; 2008
   Google Scholar
• Smyk-Pearson S, Tester IA, Lezotte D, Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 2006;194(4):454-63
   PubMedGoogle Scholar
• Chiron, Inc. Novel HCV non-structural polypeptides. US2006057164; 2006
   Google Scholar
• Okairos AG Switzerland. Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof. WO2010086189; 2010
   Google Scholar
• Colloca S, Folgori A, LAHM A. Hepatitis C virus nucleic acid vaccine. US2009035277; 2009
   Google Scholar
• Transgene SA. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use. US2007269460; 2007
   Google Scholar
• Dahari H, Feinstone S, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010;139(3):965-74
   PubMed Web of Science ®Google Scholar
• Chiron Corp. NANBV diagnostics and vaccines. US6150087; 2000
   Google Scholar
• Chiron Corp. NANBV diagnostics and vaccines. US6346375; 2002
   Google Scholar
• Chiron Corp. NANBV diagnostics and vaccines. EP0388232; 2005
   Google Scholar
• GlobeImmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection. US2010150963; 2010
   Google Scholar
• Novartis Vaccines & Diagnostic. Conserved motif of hepatitis C virus E2/NS1 region. US0823980; 1997
   Google Scholar
• Chiron Corp. Immunoassays for anti-HCV antibodies using antigens with conformational epitopes. WO9401778; 1994
   Google Scholar
• Innogenetics NV. HCV compositions. WO2004041853; 2004
   Google Scholar
• Innogenetics NV. Immunodominant human T-cell epitopes of hepatitis C virus. WO9512677; 1995
   Google Scholar
• Epimmune, Inc. Inducing cellular immune responses to hepatitis C virus using peptide and nucleic acid compositions. WO0121189; 2001
   Google Scholar
• Scripps Research Inst. Peptides for inducing cytotoxic T lymphocyte responses to hepatitis C virus. WO9525122; 1995
   Google Scholar
• Innogenetics N.V. and IDM Pharma, Inc. Peptides for inducing a CTL and/or HTL responses to Hepatitis C virus. WO118626A2; 2005
   Google Scholar
• Lauer GM, Barnes E, Lucas M, High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004;127(3):924-36
   PubMedGoogle Scholar
• Schulze zurWiesch J, Lauer GM, Day CL, Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005;175(6):3603-13
   PubMedGoogle Scholar
• Dazert E, Neumann-Haefelin C, Bressanelli S, Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009;119(2):376-86
   PubMedGoogle Scholar
• Wedemeyer H, He X-S, Nascimbeni M, Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002;169(6):3447-58
   PubMedGoogle Scholar
• Cooper S, Erickson AL, Adams EJ, Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10(4):439-49
   PubMed Web of Science ®Google Scholar
• Lasarte J-J, Garcia-Granero M, Lopez A, Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998;28(3):815-22
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Fisicaro P, Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006;44:126-39
   PubMed Web of Science ®Google Scholar
• Day CL, Seth NP, Lucas M, Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003;112(6):831-42
   PubMed Web of Science ®Google Scholar
• Frisch J, Tauber E, Buerger V, HCV vaccines for chronic HCV patients. US2010322972; 2010
   Google Scholar
• Chiron Corp. Hepatitis C virus multi copy epitope fusion antigens. US6428792; 2002
   Google Scholar
• Epimmune, Inc. Inducing cellular immune responses to Hepatitis C virus using peptide and nucleic acid compositions. WO0121189; 2001
   Google Scholar
• Arashkia A, Roohvand F, Memarnejadian A, Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes 2010;40(1):44-52
   PubMedGoogle Scholar
• Memarnejadian A, Roohvand F, Arashkia A, Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 2009;16(7):842-50
   PubMedGoogle Scholar
• Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol 2010;261(2):9
   PubMedGoogle Scholar
• McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000;7:2-14
   PubMed Web of Science ®Google Scholar
• Roohvand F, Maillard P, Lavergne JP, Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J Biol Chem 2009;284(20):13778-91
   PubMed Web of Science ®Google Scholar
• Schulzezur WJ, Schmitz H, Borowski E, The proteins of the Hepatitis C virus: their features and interactions with intracellular protein phosphorylation. Arch Virol 2003;148:1247-67
   PubMedGoogle Scholar
• Piodi A, Chouteau P, Lerat H, Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008;48:16-27
   PubMed Web of Science ®Google Scholar
• Fishman SL, Factor SH, Balestrieri C, Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 2009;15:3205-13
   PubMed Web of Science ®Google Scholar
• Soguero C, Joo M, Chianese-Bullock KA, Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 2002;76(18):9345-54
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Fujie H, Shintani Y, Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005;43:757-63
   PubMedGoogle Scholar
• Lin W, Kim SS, Yeung E, Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006;80:9226-35
   PubMed Web of Science ®Google Scholar
• Tsai S, Chen Y, Chen M. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998;115:954
   PubMedGoogle Scholar
• Christie JM, Chapel H, Chapman RW, Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology 1999;30:1037
   Google Scholar
• US Health. Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure. WO9527733; 1995
   Google Scholar
• Glaxo Group Ltd. Immunogenic compositions. US2009232847; 2009
   Google Scholar
• CSL Ltd and Chiron Corp. Vaccine compositions. US2010047271; 2010
   Google Scholar
• Pasteur Merieux Serums Vacc.Vaccine composition for preventing or treating hepatitis. US2002034734; 2002
   Google Scholar
• Roohvand F, Aghasadeghi MR, Sadat SM, HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 2007;354(3):641-9
   PubMedGoogle Scholar
• Green Peptide Co. Ltd. Peptide derived from hepatitis C virus. US2010292138; 2010
   Google Scholar
• Brierley I. Ribosomal frame-shifting on viral RNAs. J Gen Virol 1995;76:1885-92
   PubMed Web of Science ®Google Scholar
• Walewski JL, Keller TR, Stump DD, Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001;7:710-21
   PubMedGoogle Scholar
• Vassilaki N, Mavromara P. The HCV ARFP/F/Core +1 protein: production and functional analysis of an unconventional viral product. IUBMB Life 2009;61(7):739-52
   PubMedGoogle Scholar
• Pasteur Institut. Novel HCV Core+1 protein, methods for diagnosis of HCV infections, prophylaxis and for screening of anti-HCV agents. WO2005005468; 2005
   Google Scholar
• Transgene and Centre Nat Rech Scient. Mutated nucleotide sequences of the hepatitis C virus. WO2006134280; 2006
   Google Scholar
• Branch AD, Walewski JL, Stump DD. Alternate reading frame polypeptides derived from hepatitis C and methods of their use. WO2005010035; 2005
   Google Scholar
• Bullock TN, Eisenlohr LC. Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J Exp Med 1996;184(4):1319-29
   PubMedGoogle Scholar
• Okairos AG. A vaccine for the prevention and therapy of HCV vaccine. WO2009146902; 2009
   Google Scholar
• Helle F, Wychowski C, Vu-Dac N, Cyanovirin-n inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006;281:25177-83
   PubMed Web of Science ®Google Scholar
• US Gov Health & Human Serv. Genomic nucleic acid sequence for cyanovirin-N (CV-N) and signal peptide thereof. WO2007005766; 2007
   Google Scholar
• Osel, Inc. Modified cyanovirin-N (CV-N) polypeptide. WO2006083516; 2006
   Google Scholar
• Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002;195:43-9
   PubMed Web of Science ®Google Scholar
• Logvinoff C, Major ME, Oldach D, Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004;101(27):10149-54
   PubMed Web of Science ®Google Scholar
• Prentoe J, Jensen TB, Meuleman P, Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 2011;85(5):2224-34
   PubMed Web of Science ®Google Scholar
• von HT, Yoon JC, Alter H, Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132(2):667-78
   PubMedGoogle Scholar
• Helle F, Goffard A, Morel V, The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007;81(15):8101-11
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96(2):12766-71
   PubMedGoogle Scholar
• EPIXIS. Method for enhancing the potency of HCV neutralizing antibodies. WO2006103493; 2006
   Google Scholar
• Chiron Corp. HCV E1E2 vaccine compositions. US2009258033; 2009
   Google Scholar
• Univ Francois Rabelais de Tour (FR). Novel fusion proteins and use thereof for preparing hepatitis C vaccines. WO2009153518; 2009
   Google Scholar
• Leroux-Roels G, Batens AH, Desombere I, Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005;1(2):61-5
   PubMed Web of Science ®Google Scholar
• Novartis Vaccines & Diagnostic. Eliciting HCV-specific antibodies. US2008095800; 2008
   Google Scholar
• US Health. Surface targeted expression of a modified hepatitis C virus envelope protein. WO9966033; 1999
   Google Scholar
• Innogenetics NV. Recombinant vectors for producing HCV envelope proteins. EP1211315; 2002
   Google Scholar
• Innogenetics. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use. US20010260699; 2005
   Google Scholar
• Scripps Research Inst. HCV neutralizing epitopes. US2010104555; 2010
   Google Scholar
• Scripps Research Inst. Mutant hepatitis C virus E2 polypeptide for HCV treatment. WO2010047829; 2010
   Google Scholar
• Genmab AS. Anti-hepatitis C virus antibody and uses thereof. US2009104188; 2009
   Google Scholar
• Univ Leland Stanford Junior. Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes. WO2006041866; 2006
   Google Scholar
• Kubanek Bernard. Human monoclonal antibody against hepatitis c virus E2 glycoprotein. US2004071710; 2004
   Google Scholar
• Zhang P, Zhong L, Struble EB, Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 2009;106(18):7537-41
   PubMed Web of Science ®Google Scholar
• Perotti M, Mancini N, Diotti RA, Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82(2):1047-52
   PubMed Web of Science ®Google Scholar
• Meunier J-C, Russell RS, Goossens V, Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 2008;82(2):966-73
   PubMed Web of Science ®Google Scholar
• Law M, Maruyama T, Lewis J, Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-7
   PubMed Web of Science ®Google Scholar
• David R. Use of HCV P7 protein. US2006252918; 2006
   Google Scholar
• Univ Oxford. Use of iminosugar derivatives to inhibit ion channel activity. KR20050092103; 2005
   Google Scholar
• Pietschmann T, Kaul A, Koutsoudakis G, Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006;103:7408-13
   PubMed Web of Science ®Google Scholar
• Istituto Di Ricerche Di Biologia Molecolare. HCV NS2/3 fragments and uses there of. US2004054134; 2004
   Google Scholar
• Uebelhoer L, Han J-H, Callendret B, Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 2008;4(9):e1000143
   Google Scholar
• Tibotec Pharm Ltd. HCV NS3-3 serine protease inhibitors. EP1881002 and EP1881001; 2008
   Google Scholar
• Vertex Pharma. HCV NS3-NS4A protease inhibition using VX-950, also known as telaprevir. US2011059886;2011
   Google Scholar
• Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res 2010;131:17-34
   PubMed Web of Science ®Google Scholar
• Innogenetics NV. HCV NS3 proteins and nucleic acids. EP1555270; 2005
   Google Scholar
• Tripep AB. Hepatitis C virus codon optimized non-structural NS3/4A fusion gene. US2010104592; 2010
   Google Scholar
• Tripep AB. Immunogen platform. US2009214593; 2009
   Google Scholar
• Blight KJ. Allelic variation in the hepatitis C virus NS4B protein dramatically influences RNA replication. J Virol 2007;81:5724-36
   PubMedGoogle Scholar
• Innogenetics NV. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays. US6165730; 2000
   Google Scholar
• Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. Plos Pathog 2008;4:e1000032
   PubMed Web of Science ®Google Scholar
• Kriegs M, Burckstummer T, Himmelsbach K, The hepatitis C virus non structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 2009;284:28343-51
   PubMedGoogle Scholar
• Lemm JA, O'Boyle D, Liu M, Identification of hepatitis C virus NS5A inhibitors. J Virol 2010;84(1):482-91
   PubMed Web of Science ®Google Scholar
• Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15(1):41-63
   PubMed Web of Science ®Google Scholar
• Centocor Ortho Biotech Product and Medivir A. Phosphoramidate derivatives of nucleosides. EP2166016; 2010
   Google Scholar
• Lloyd AR, Jagger E, Post JJ, Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007;85:24-32
   PubMedGoogle Scholar
• Pestka JM, Zeisel MB, Blaser E, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-30
   PubMed Web of Science ®Google Scholar
• Youn JW, Park SH, Lavillette D, Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005;42(6):1429-36
   PubMed Web of Science ®Google Scholar
• Osburn WO, Fisher BE, Dowd KA, Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010;138(1):315-24
   PubMed Web of Science ®Google Scholar
• Grant MD. Anti-idiotypic antibody and its use in diagnosis and therapy of hepatitis C virus related diseases. US2004146857; 2004
   Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ, HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-62
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52
   PubMed Web of Science ®Google Scholar
• Semmo N, Day CL, Ward SM, Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005;41(5):1019-28
   PubMedGoogle Scholar
• Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specifi c T-cell responses in hepatitis C virus infection. Genes Immun 2007;8:181-92
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798-801
   PubMed Web of Science ®Google Scholar
• Randall G, Chen L, Panis M, Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006;131:1584-91
   PubMed Web of Science ®Google Scholar
• Univ California. CD127 expression inversely correlates with FOXP3 and suppressive function of CD4+ tregs. WO2007140472; 2007
   Google Scholar
• Merck & Co, Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-GAG, POL, NEF and modifications. WO0222080; 2002
   Google Scholar
• Folgori A, Capone S, Ruggeri L, A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12(2):190-7
   PubMed Web of Science ®Google Scholar
• Angeletti P Inst Richerche Bio. Hepatitis C virus nucleic acid vaccine. US2009035277; 2009
   Google Scholar
• Zubkova I, Choi YH, Chang E, T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009;27(19):2594-602
   PubMedGoogle Scholar
• Frazier AD, Zhang CL, Ni L, Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection. Viral Immunol 2010(5):487-9
   PubMedGoogle Scholar
• Zhang Y, Ma CJ, Ni L, Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol 2011;186(5):3093-103
   PubMedGoogle Scholar
• Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011;203(5):635-45
   PubMedGoogle Scholar
• Smyk Pearson S, Golden Mason L, Klarquist J, Functional suppression by FoxP31CD41CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008;197:46-57
   PubMedGoogle Scholar
• Sturm N, Thelu MA, Camous X, Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010;53(1):25-35
   PubMedGoogle Scholar
• Buschle M, Frisch J, Klade C, HCV vaccines. US2009130135; 2009
   Google Scholar
• Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ Tcells during acute HCV infection, irrespective of clinical outcome. J Virol 2008;82:3154-60
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D, Cross-genotype immunity to hepatitis C virus. J Virol 2004;78:1575-81
   PubMed Web of Science ®Google Scholar
• Garcia F Jr, Garcia F, Roldan C, Detection of HCV and GBV-CHGV RNA in peripheral blood mononuclear cells of patients with chronic type C hepatitis. Microbios 2000;103:7-15
   PubMedGoogle Scholar
• Inst Nat Sante Rech Med. Novel human hepatoma lines, methods for obtaining same and uses thereof. WO03004627; 2003
   Google Scholar
• Hvidover Hospital. Adaptive mutations allow establishment of JFH1-based cell culture systems for Hepatitis C Virus genotype 4A. WO2008125119; 2008
   Google Scholar
• Hvidovre Hospital. Efficient cell culture system for hepatitis C virus genotype 2b. WO2010017818; 2010
   Google Scholar
• Hvidovre Hospital. Efficient cell culture system for hepatitis C Virus genotype 5A. WO2008141651; 2008
   Google Scholar
• Hvidovre Hospital. Efficient cell culture system for hepatitis C Virus genotype 6A. WO2009080052; 2009
   Google Scholar
• Hvidovre Hospital. Efficient cell culture system for hepatitis C Virus genotype 7a. WO2010017819; 2010
   Google Scholar
• Hidovert Hospital. Efficient cell culture system for hepatitis C virus genotype 1A and 1B. WO2009080053; 2009
   Google Scholar
• Scheel TK, Gottwein JM, Jensen TB, Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci USA 2008;105(3):997-1002
   PubMedGoogle Scholar
• Postech Acad Ind found. An efficiently replicartive Hepatitis C Virus mutant, a HCV mutant comprising reporter gene, a method of preparing of HCV vaccine using the same and a method of screening anti HCV composition the same. WO2008133468; 2008
   Google Scholar
• Hvidovre Hospital. Hepatitis C virus expressing reporter tagged NS5A protein. WO2010037403; 2010
   Google Scholar
• Tory Industries. Nucleic acid containing chimeric gene derived from hepatitis Type-C. WO2009131203; 2009
   Google Scholar
• Takahashi H, Akazawa D, Kato T, Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. Biochem Biophys Res Commun 2010;395:565-71
   PubMedGoogle Scholar
• Lerat H, Higgs M, Pawlotsky JM. Animal models in the study of hepatitis C virus-associated liver pathologies. Expert Rev Gastroenterol Hepatol 2011;5(3):341-52
   PubMed Web of Science ®Google Scholar
• Mercer DF. Animal models for studying hepatitis C and alcohol effects on liver. World J Gastroenterol 2011;17(20):2515-19
   PubMedGoogle Scholar
• Univ Rockefeller. New HCV entry factor, occludin. WO2010040001; 2010
   Google Scholar
• Couto LB, Kolykhalov AA. Chapter 12 animal models for HCV study. In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology. Horizon Bioscience; Norfolk (UK): 2006. p. 353-74
   Google Scholar
• Dittmer DP, Floyd RA. RNA virus vaccines and methods. WO2007094854; 2007
   Google Scholar